Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment

被引:69
作者
D'Uva, Gabriele [1 ]
Baci, Denisa [1 ]
Albini, Adriana [1 ]
Noonan, Douglas M. [1 ,2 ]
机构
[1] IRCCS MultiMed, Sci & Technol Pole, Milan, Italy
[2] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy
关键词
Chemoprevention; Angioprevention; Cancer; Microenvironment; Inflammation; Angiogenesis; Phytochemicals; CYP1; enzymes; CYP1B1; ARYL-HYDROCARBON RECEPTOR; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; CYP1B1 DETERMINES SUSCEPTIBILITY; POLYCYCLIC AROMATIC-HYDROCARBONS; INHIBITS VEGF EXPRESSION; ANTI-ANGIOGENIC ACTIVITY; UP-REGULATION;
D O I
10.1016/j.ctrv.2017.10.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer chemoprevention is the use of synthetic, natural or biological agents to prevent or delay the development or progression of malignancies. Intriguingly, many phytochemicals with anti-inflammatory and anti-angiogenic effects, recently proposed as chemoprevention strategies, are inhibitors of Cytochrome P450 family 1B1 (CYP1B1), an enzyme overexpressed in a wide variety of tumors and associated with angiogenesis. In turn, pro-inflammatory cytokines were reported to boost CYP1B1 expression, suggesting a key role of CYP1B1 in a positive loop of inflammatory angiogenesis. Other well-known pro-tumorigenic activities of CYP1B1 rely on metabolic bioactivation of xenobiotics and steroid hormones into their carcinogenic derivatives. In contrast to initial in vitro observations, in vivo studies demonstrated a protecting role against cancer for the other CYP1 family members (CYP1A1 and CYP1A2), suggesting that the specificity of CYP1 family inhibitors should be carefully taken into account for developing potential chemoprevention strategies. Recent studies also proposed a role of CYP1B1 in multiple cell types found within the tumor microenvironment, including fibroblasts, endothelial and immune cells. Overall, our review of the current literature suggests a positive loop between inflammatory cytokines and CYP1B1, which in turn may play a key role in cancer angiogenesis, acting on both cancer cells and the tumor microenvironment. Strategies aiming at specific CYP1B1 inhibition in multiple cell types may translate into clinical chemoprevention and angioprevention approaches. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 262 条
[1]   Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol:: NF-κB and Akt as targets [J].
Albini, A ;
Dell'Eva, R ;
Vené, R ;
Ferrari, N ;
Buhler, DR ;
Noonan, DM ;
Fassina, G .
FASEB JOURNAL, 2005, 19 (14) :527-+
[2]   Tumor inflammatory angiogenesis and its chemoprevention [J].
Albini, A ;
Tosetti, F ;
Benelli, R ;
Noonan, DM .
CANCER RESEARCH, 2005, 65 (23) :10637-10641
[3]   The tumour microenvironment as a target for chemoprevention [J].
Albini, Adriana ;
Sporn, Michael B. .
NATURE REVIEWS CANCER, 2007, 7 (02) :139-147
[4]   Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids [J].
Androutsopoulos, Vasilis P. ;
Papakyriakou, Athanasios ;
Vourloumis, Dionisios ;
Spandidos, Demetrios A. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (09) :2842-2849
[5]   Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes [J].
Androutsopoulos, Vasilis P. ;
Papakyriakou, Athanasios ;
Vourloumis, Dionisios ;
Tsatsakis, Aristidis M. ;
Spandidos, Demetrios A. .
PHARMACOLOGY & THERAPEUTICS, 2010, 126 (01) :9-20
[6]  
[Anonymous], 2015, J NANOMATER
[7]  
Badal S, 2013, OA BIOCHEM, V1, P1
[8]   Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity [J].
Bagli, E ;
Stefaniotou, M ;
Morbidelli, L ;
Ziche, M ;
Psillas, K ;
Murphy, C ;
Fotsis, T .
CANCER RESEARCH, 2004, 64 (21) :7936-7946
[9]   Cytochrome P450 1B1:: A major P450 isoenzyme in human blood monocytes and macrophage subsets [J].
Baron, JM ;
Zwadlo-Klarwasser, G ;
Jugert, F ;
Hamann, W ;
Rübben, A ;
Mukhtar, H ;
Merk, HF .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (09) :1105-1110
[10]   Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506